BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37310401)

  • 1. A novel prognostic signature contributes to precision treatment in colon adenocarcinoma with KRAS mutation.
    Dong W; Zhang H; Li Q; Guan N; Yun C; Zhao H; Zhang F; Zeng Z; Hu Y; Li Q; Yang J; Ma Z; Chen M; Xiao W
    Eur J Cancer Prev; 2023 Nov; 32(6):557-565. PubMed ID: 37310401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel strategy for precise prognosis management and treatment option in colon adenocarcinoma with TP53 mutations.
    Niu L; Liu L; Cai J
    Front Surg; 2023; 10():1079129. PubMed ID: 36843983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. To explore the prognostic characteristics of colon cancer based on tertiary lymphoid structure-related genes and reveal the characteristics of tumor microenvironment and drug prediction.
    Wang Z; Niu D
    Sci Rep; 2024 Jun; 14(1):13555. PubMed ID: 38867070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y
    Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904
    [No Abstract]   [Full Text] [Related]  

  • 5. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
    Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose metabolism-based signature predicts prognosis and immunotherapy strategies for colon adenocarcinoma.
    Bai Z; Yan C; Nie Y; Zeng Q; Xu L; Wang S; Chang D
    J Gene Med; 2024 Jan; 26(1):e3620. PubMed ID: 37973153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a Four-Gene Metabolic Signature to Evaluate the Prognosis of Colon Adenocarcinoma Patients.
    Zheng Y; Wu R; Wang X; Yin C
    Front Public Health; 2022; 10():860381. PubMed ID: 35462848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
    Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Models for Colon Adenocarcinoma Diagnosis, Prognosis, and Immune Microenvironment Based on 2 Hypoxia-Related Genes: KDM3A and ENO3.
    Kong C; Zheng L; Fang S; Chen M; Lin G; Qiu R; Zhao Z; Chen W; Song J; Yang Y; Ji J
    Technol Cancer Res Treat; 2023; 22():15330338231195494. PubMed ID: 37650153
    [No Abstract]   [Full Text] [Related]  

  • 10. Metabolism-related lncRNAs signature to predict the prognosis of colon adenocarcinoma.
    Sun Y; Liu B; Xiao B; Jiang X; Xiang JJ; Xie J; Hu XM
    Cancer Med; 2023 Mar; 12(5):5994-6008. PubMed ID: 36366731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
    Xu M; Mu J; Wang J; Zhou Q; Wang J
    Front Oncol; 2022; 12():961213. PubMed ID: 35965536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A potential prognostic prediction model of colon adenocarcinoma with recurrence based on prognostic lncRNA signatures.
    Jin L; Li C; Liu T; Wang L
    Hum Genomics; 2020 Jun; 14(1):24. PubMed ID: 32522293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a prognostic model for personalized prediction of colon adenocarcinoma (COAD) patient outcomes using methylation-driven genes.
    Chen D; Zhang B; Kang K; Li L; Liao Y; Qing S; Di Y
    J Appl Genet; 2023 Dec; 64(4):713-721. PubMed ID: 37589877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel prognostic signature composed of 3 cuproptosis-related transcription factors in colon adenocarcinoma.
    Zhou L; Zhang Y; Xu Y; Jiang T; Tang L
    Genes Genomics; 2023 Aug; 45(8):1047-1061. PubMed ID: 37318704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel signature model based on mitochondrial-related genes for predicting survival of colon adenocarcinoma.
    Gao H; Xing F
    BMC Med Inform Decis Mak; 2022 Oct; 22(1):277. PubMed ID: 36273131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel enterocyte-related 4-gene signature for predicting prognosis in colon adenocarcinoma.
    Cheng X; Wei Y; Fu Y; Li J; Han L
    Front Immunol; 2022; 13():1052182. PubMed ID: 36532007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel machine learning model based on ubiquitin-related gene pairs and clinical features to predict prognosis and treatment effect in colon adenocarcinoma.
    Liang L; Liu L; Mai S; Chen Y
    Eur J Med Res; 2023 Jan; 28(1):41. PubMed ID: 36681855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic implications of ferroptosis-associated gene signature in colon adenocarcinoma.
    Miao YD; Kou ZY; Wang JT; Mi DH
    World J Clin Cases; 2021 Oct; 9(29):8671-8693. PubMed ID: 34734046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circadian Clock Genes Are Correlated with Prognosis and Immune Cell Infiltration in Colon Adenocarcinoma.
    He A; Huang Z; Zhang R; Lu H; Wang J; Cao J; Feng Q
    Comput Math Methods Med; 2022; 2022():1709918. PubMed ID: 35116071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lactate Metabolism-Associated lncRNA Pairs: A Prognostic Signature to Reveal the Immunological Landscape and Mediate Therapeutic Response in Patients With Colon Adenocarcinoma.
    Xiao J; Wang X; Liu Y; Liu X; Yi J; Hu J
    Front Immunol; 2022; 13():881359. PubMed ID: 35911752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.